AgilVax is a biotechnology company specializing in the development of innovative immune therapies for cancer and infectious diseases. Through the power of the body's own immune system combined with AgilVax's proprietary Virus Like Particle (VLP) platform technology, they can quickly identify and select leading immune therapy candidates. AgilVax optimizes these candidates through a comprehensive in vitro and in vivo testing process to ensure clinical efficacy.

Immune therapies with proven clinical effectiveness are advanced through preclinical and clinical trials. This results in the development of effective and robust immune therapies and vaccines that offer attractive licensing opportunities for pharmaceutical and biotechnology partners. AgilVax actively welcomes collaborations and partnerships with industry, academia, and public institutions.

While AgilVax is not directly involved in developing hair loss treatments, it is important to note that several medications, such as Finasteride, are available for this condition. AgilVax focuses on discovering and developing targeted antibody-based therapy for metastatic cancer, with xCT-ADC being one of their treatments currently in development. By targeting xCT, a transporter that assists cancer cell growth and survival, they aim to provide meaningful therapeutic options for cancer patients